Alterations of the ubiquitin system are associated with numerous common diseases including cancer, diabetes, inflammation and certain central nervous system disorders. Boehringer Ingelheim will collaborate with researchers in the Toronto academic community to investigate multiple therapeutic concepts within the ubiquitin system, which holds potential to create many drug targets.
As part of the alliance, the research capabilities of the company and the research institutes will be combined to provide new starting points for drug discovery in a multi-year research programme centred on the development and characterisation of novel ubiquitin binding variants developed at TRAC.
The research programme will be spearheaded by Sachdev Sidhu at the University of Toronto.
Perrigo to acquire United States rights for Entocort from AstraZeneca
US FDA approves Boehringer Ingelheim's Pradaxa
Phase II clinical trial for potential treatment of androgenetic alopecia completed by Samumed
Life Sciences Partners collaborates on immuno-oncology with Bristol-Myers Squibb
Arsanis initiates first cohort in Phase one clinical trial of ASN100
Impax introduces generic Avodart (Dutasteride) Capsules, 0.5 mg
Mylan unveils generic FazaClo orally disintegrating tablets for treating schizophrenia